Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
Silexion Therapeutics has successfully submitted a Clinical Trial Application to Germany's BfArM for its Phase 2/3 study of SIL204, an innovative siRNA therapy targeting KRAS-driven locally advanced pancreatic cancer. This regulatory milestone follows Israeli approval and marks the company's expansion into the European clinical development landscap…